Is olaparib the only PARP inhibitor that has been approved?
- 1 people answered
Edit Tags
Tags are used to find the best answers
You might also be interested in
Be thankful if you are lactose intolerant because it could save you from certain cancers including breast cancer. Some researchers from Sweden said in 2014 that people who are lactose intolerant might be less likely to develop lung, breast and ovarian cancers. Low dairy consumption seems to reduce t....
There are few things more alarming than battling cancer. One is not having the money for its treatment. Given the recent spike in incidence of cancer and its treatment costs, this could soon be a reality than mere speculation. At present breast cancer treatment in India costs almost 6 lakhs, while i....
The American Cancer Society recommends these cancer screening guidelines for most adults. Screening tests are used to find cancer before a person has any symptoms. Women aged 40 to 44 should have the choice to start annual breast cancer screening with mammograms (x-rays of the breast) if they wish t....
Credihealth is not a medical practitioner and does not provide medical advice. You should consult your doctor or with a healthcare professional before starting any diet, exercise, supplementation or medication program. Know More
எழுதியவர்:Dr. Nitika Sharma - BDS
மதிப்பிட்டவர்:Dr. Rakesh Kumar - MBBS, MS
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.